Vanda (VNDA) Ramps; Lazard Sees Upside

Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) ramped on Friday. The move is being traced to "exceptionally positive" feedback for Vanda's experimental tasimelteon to treat non-24-hour disorder.

Feedback was pointed out by analyst Joshua Schimmer of Lazard Capital. He thinks Vanda is well ahead of the game in raising awareness about non-24 hour. He also sees plenty of upside in the stock.

Lazard has a Buy rating on Vanda Pharmaceuticals with a price target of $17.00.

For an analyst ratings summary and ratings history on Vanda Pharmaceuticals (NASDAQ: VNDA) click here. For more ratings news on Vanda Pharmaceuticals click here.

Shares of Vanda Pharmaceuticals closed at $7.12 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Upgrades Sirius XM Radio (SIRI) to Buy, 'mispriced based on a large disconnect between consensus estimates and what we believe the company can achieve
• MongoDB (MDB) PT Lowered to $410 at UBS Following Earnings
• salesforce.com (CRM) PT Raised to $300 at Cantor Fitzgerald as 'Stock Deserves a Higher Multiple'